Kura Oncology (NASDAQ:KURA) CEO Acquires $754,462.03 in Stock

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Wilson purchased 98,881 shares of the company’s stock in a transaction dated Friday, November 13th. The stock was purchased at an average price of $7.63 per share, with a total value of $754,462.03. Following the transaction, the chief executive officer owned 534,337 shares of the company’s stock, valued at approximately $4,076,991.31. This represents a 22.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Troy Edward Wilson also recently made the following trade(s):

  • On Monday, November 16th, Troy Wilson acquired 101,119 shares of Kura Oncology stock. The shares were bought at an average price of $7.42 per share, for a total transaction of $750,302.98.
  • On Monday, August 24th, Troy Wilson purchased 100,000 shares of Kura Oncology stock. The stock was acquired at an average cost of $12.39 per share, with a total value of $1,239,000.00.

Kura Oncology Stock Down 2.0%

Shares of KURA stock opened at $7.34 on Thursday. The firm has a fifty day moving average of $9.85 and a two-hundred day moving average of $9.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.60 and a quick ratio of 3.56. Kura Oncology, Inc. has a 1-year low of $6.75 and a 1-year high of $13.90.

Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%. The company had revenue of $22.84 million during the quarter, compared to analyst estimates of $24.94 million. On average, sell-side analysts anticipate that Kura Oncology, Inc. will post -3.20 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KURA has been the subject of a number of recent analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Thursday, November 12th. Deutsche Bank set a $24.00 price target on Kura Oncology in a report on Wednesday, October 14th. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. JPMorgan Chase & Co. started coverage on Kura Oncology in a research note on Thursday, October 1st. They set an “overweight” rating and a $30.00 target price for the company. Finally, UBS Group set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, November 12th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $25.88.

Check Out Our Latest Research Report on KURA

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Kura Oncology during the second quarter valued at $115,286,000. Algert Global LLC purchased a new stake in shares of Kura Oncology in the 3rd quarter worth $13,976,000. Bank of America Corp DE purchased a new stake in shares of Kura Oncology during the 2nd quarter worth $12,735,000. Dimensional Fund Advisors LP raised its stake in Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after buying an additional 348,127 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Kura Oncology during the 2nd quarter valued at approximately $10,927,000.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

See Also

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.